Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ranibizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Byooviz

    02 20Lucentis

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Roche

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2019 Revenue in Millions : 1,881

    2018 Revenue in Millions : 1,709

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Roche

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 1,609

    2019 Revenue in Millions : 2,034

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Novartis

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 1,933

    2019 Revenue in Millions : 2,086

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Novartis

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 2,160

    2020 Revenue in Millions : 1,933

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Roche

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 1,456

    2020 Revenue in Millions : 1,531

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Novartis

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 1,874

    2021 Revenue in Millions : 2,160

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Byooviz

    Ranibizumab-nuna

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Byooviz

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Biogen

    Ranibizumab-nuna

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 4

    2021 Revenue in Millions : 0

    Growth (%) : New Launch in 2022

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Roche

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 1,106

    2021 Revenue in Millions : 1,456

    Growth (%) : -24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Byooviz

    Ranibizumab-nuna

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Byooviz

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Biogen

    Ranibizumab-nuna

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2023 Revenue in Millions : 32

    2022 Revenue in Millions : 4

    Growth (%) : 637

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Lucentis

    Ranibizumab

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Lucentis

    Switzerland
    arrow
    Fi Europe 2024
    Not Confirmed

    Roche

    Ranibizumab

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2023 Revenue in Millions : 534

    2022 Revenue in Millions : 1,106

    Growth (%) : -55

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF